vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $11.5M, roughly 1.6× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -25.7%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-15.8M). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
CTMX vs TACT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $11.5M |
| Net Profit | $-154.0K | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -6.9% | -10.1% |
| Net Margin | -0.8% | — |
| Revenue YoY | -25.7% | 11.9% |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $13.2M | ||
| Q2 25 | $18.7M | $13.8M | ||
| Q1 25 | $50.9M | $13.1M | ||
| Q4 24 | $38.1M | $10.2M | ||
| Q3 24 | $33.4M | $10.9M | ||
| Q2 24 | $25.1M | $11.6M | ||
| Q1 24 | $41.5M | $10.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $15.0K | ||
| Q2 25 | $-154.0K | $-143.0K | ||
| Q1 25 | $23.5M | $19.0K | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-551.0K | ||
| Q2 24 | $-6.5M | $-319.0K | ||
| Q1 24 | $13.8M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | — | -10.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | -6.9% | -1.9% | ||
| Q1 25 | 44.4% | -0.1% | ||
| Q4 24 | 46.4% | -10.3% | ||
| Q3 24 | 12.3% | -7.7% | ||
| Q2 24 | -33.7% | -3.8% | ||
| Q1 24 | 28.1% | -12.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | -0.8% | -1.0% | ||
| Q1 25 | 46.2% | 0.1% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -5.1% | ||
| Q2 24 | -26.0% | -2.8% | ||
| Q1 24 | 33.3% | -9.7% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $31.1M |
| Total Assets | $175.1M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.4M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | $49.0M | $17.7M | ||
| Q1 25 | $47.6M | $14.2M | ||
| Q4 24 | $38.1M | $14.4M | ||
| Q3 24 | $40.6M | $11.3M | ||
| Q2 24 | $43.2M | $11.1M | ||
| Q1 24 | $36.2M | $10.6M |
| Q4 25 | — | $31.1M | ||
| Q3 25 | — | $31.8M | ||
| Q2 25 | $119.9M | $31.3M | ||
| Q1 25 | $25.0M | $30.9M | ||
| Q4 24 | $-456.0K | $30.6M | ||
| Q3 24 | $-23.5M | $38.4M | ||
| Q2 24 | $-31.2M | $38.5M | ||
| Q1 24 | $-31.7M | $38.6M |
| Q4 25 | — | $44.8M | ||
| Q3 25 | — | $45.0M | ||
| Q2 25 | $175.1M | $44.5M | ||
| Q1 25 | $98.5M | $44.2M | ||
| Q4 24 | $120.5M | $44.0M | ||
| Q3 24 | $139.0M | $50.5M | ||
| Q2 24 | $159.2M | $50.4M | ||
| Q1 24 | $184.7M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $609.0K |
| Free Cash FlowOCF − Capex | $-15.8M | $589.0K |
| FCF MarginFCF / Revenue | -84.6% | 5.1% |
| Capex IntensityCapex / Revenue | 0.1% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $609.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-15.8M | $3.6M | ||
| Q1 25 | $-21.0M | $-161.0K | ||
| Q4 24 | $-19.9M | $2.4M | ||
| Q3 24 | $-20.7M | $327.0K | ||
| Q2 24 | $-19.5M | $636.0K | ||
| Q1 24 | $-26.0M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-15.8M | $3.6M | ||
| Q1 25 | $-21.2M | $-171.0K | ||
| Q4 24 | $-20.0M | $2.4M | ||
| Q3 24 | $-20.7M | $259.0K | ||
| Q2 24 | $-19.6M | $499.0K | ||
| Q1 24 | $-26.2M | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | -84.6% | 25.9% | ||
| Q1 25 | -41.6% | -1.3% | ||
| Q4 24 | -52.5% | 23.2% | ||
| Q3 24 | -62.1% | 2.4% | ||
| Q2 24 | -78.2% | 4.3% | ||
| Q1 24 | -63.1% | -14.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.4% | 1.2% | ||
| Q1 24 | 0.3% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | -8.47× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
TACT
Segment breakdown not available.
